Nucleus Commercial Finance hires a new Business Development Manager

By Joy Dumasia

Nucleus Commercial Finance, the FinTech, announced that Sam Percival has joined as Business Development Manager for London and the South East. The appointment comes at a crucial time as SMEs show increased demand for finance following Covid-19 lockdown restrictions.

Sam, who previously worked for Nucleus in 2016, rejoins after serving as Regional Director at asset-backed lender Ultimate Finance for four years. Before these positions, he held various Regional Sales roles for lenders Aldermore Bank and Credit Agricole.

Sam will be responsible for driving growth and building SME relationships in London and the wider area, working across the whole of Nucleus’ product range, from Cash Flow Finance to asset-back loans.

Sam Percival, Business Development Manager, said: “It’s a really exciting time to be joining as the business continues to ramp up innovation across its products. As a fintech, Nucleus is leading the pack in harnessing technology to ensure SMEs get the critical working capital facilities they need fast. Having played a vital role lending £200 million to businesses as part of the Coronavirus Business Interruption Loan Scheme (CBILS), Nucleus’ broad product range puts the lender in a strong position to provide flexible finance as SMEs are eager to kickstart their businesses.”

Chirag Shah, CEO, Nucleus Commercial Finance, commented: “We’re delighted to have Sam return to Nucleus. Having always focused on the South East, he brings with him a strong network and passion for
helping SMEs access financing that fits their needs. Sam’s appointment is testament to our commitment to the market, continuing to build relationships with key introducer networks to get our tailored solutions into the hands of businesses that need them.”

IBS Intelligence recently reported that Nucleus Commercial Finance, one of the UK’s FinTech lenders, has announced enhancements to its Business Cash Advance (BCA) to support more SMEs as England eases Covid-19 restrictions.